Navigation Links
Fat yet muscular mouse provides clues to improving cardiovascular health
Date:11/22/2010

A fat yet muscular mouse is helping researchers learn whether more muscle improves the cardiovascular health of obese individuals.

"We are looking for ways to counteract the unhealthy effects of fat," said Dr. David Stepp, vascular biologist at the Medical College of Georgia Vascular Biology Center and co-director of MCG's Diabetes & Obesity Discovery Institute.

Obesity increases the risk for cardiovascular disease as well as diabetes, which essentially doubles the cardiovascular risk. But Stepp's laboratory research indicates more muscle could reduce that risk a theory bolstered by people who appear "fit and fat." He recently received a $450,000 exploratory grant from the National Institutes of Health to further explore the possibilities.

The fact is that people and mice with more muscle have more blood vessels, use more oxygen and energy and eliminate more glucose even sitting still than their flabbier counterparts. "Fat does not consume a lot of energy and it's not very vascular," Stepp said. "Muscle and nerves, on the other hand, generate electricity, which is one of the most energetically expensive things we do." The heart and blood vessels also thrive with increased blood flow and diabetes risk is reduced by muscles' glucose disposal capabilities.

"The question is, if nothing else changes, if you are still fat and inactive, does having big muscles improve metabolic and cardiovascular function," Stepp said.

If the answer is "yes," myostatin inhibitors, already under study for muscle wasting diseases such as muscular dystrophy, could help break the unhealthy vicious cycle of inactivity promoting obesity and obesity impeding exercise. "Giving someone myostatin inhibitors is not going to magically fix their problems, but it may give them a little bit of a performance edge that gets them up and moving," Stepp said, particularly the heaviest individuals.

The hormone myostatin which means "muscle stop" - is found at low levels during development but increases in adulthood when growth is supposed to stop. "If you express myostatin, your muscles stop growing at some point," he said. Exercise can help reduce myostatin levels and build muscle.

Stepp is studying a mouse that is a cross between "mighty mouse," a muscular rodent that lacks myostatin, and one that gets fat because of a diminished fullness sensation. The resulting mouse is literally quite a handful, said Stepp, noting that, unlike humans, mice tend not to overeat unless changes are made to food centers in the brain.

He wants to see whether the fat but muscular mouse has better cardiovascular function than its purely fat counterparts. That means looking at various related factors such as the ability to dilate blood vessels, which improves blood flow; production of antioxidants that promote inflammation and cardiovascular damage; and the heart's ability to pump blood.

These pursuits can help determine how muscle and exercise benefit the cardiovascular system as they target one of obesity's most debilitating and deadly risks.

"Even if you don't lose weight, exercise does good things. It limits metabolic damage, it limits cardiovascular damage," Stepp noted. "If we could get people over the hump where they could be stronger, they can be more active and hopefully lose some weight."


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. Blacks with muscular dystrophy die 10-12 years younger than whites: New study
2. Rochester leads international effort to improve muscular dystrophy treatment
3. Spinal muscular atrophy may also affect the heart
4. Gene Therapy Shows Promise for Muscular Dystrophy
5. Doctors use ultrasound to diagnose possible muscular trauma in professional athletes on-site
6. Heart drug effective for treating symptom of muscular dystrophy
7. Researchers discover chemical that may protect hearts of muscular dystrophy patients
8. Mouse model confirms mutated proteins role in dementia
9. Mouse Study Reveals a Cancer Cell Escape Route
10. Mouse Study May Help Explain Fish Oils Benefits
11. Treatment for S. aureus skin infection works in mouse model
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Fat yet muscular mouse provides clues to improving cardiovascular health
(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: